77 results on '"PSOTKA, MITCHELL"'
Search Results
2. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
3. Treatment Effects Of Empagliflozin In Hospitalized Heart Failure Patients Across The Range Of Left Ventricular Ejection Fraction - Results From The EMPULSE Trial
4. Variation Of Prespecified Subgroups In Large-Scale HF Outcome Trials
5. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
6. UNCOMMON BUT NOT UNSEEN: A RARE CAUSE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
7. BILIRUBIN ELEVATION AND OUTCOMES IN EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) SUPPORT
8. Advanced Practice Provider Urgent Outpatient Clinic for Patients With Decompensated Heart Failure
9. AN UNCOMMON CAUSE OF HEART FAILURE: ACROMEGALIC CARDIOMYOPATHY CULMINATING IN ORTHOTOPIC HEART TRANSPLANTATION
10. UTILIZATION OF GUIDELINE DIRECTED MEDICAL THERAPY FOR HEART FAILURE IN CARDIOGENIC SHOCK SURVIVORS: AN INOVA SHOCK REGISTRY ANALYSIS
11. A SMOKED HEART: CORONARY ARTERY SPASM AND CARDIOGENIC SHOCK DUE TO ACUTE CARBON MONOXIDE POISONING
12. Functional and Symptomatic Clinical Trial Endpoints
13. The evolving landscape of pulmonary arterial hypertension clinical trials
14. A Standardized and Regionalized Network of Care for Cardiogenic Shock
15. Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results from The Empulse Trial
16. Expenditure on Heart Failure in the United States
17. The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction
18. Exploring Physician Perceptions of the 2018 United States Heart Transplant Allocation System
19. Predicting Cardiac Structural And Functional Improvement On Left Ventricular Assist Device Support: The Externally Validated UCAR Score
20. IS IT TIME TO UPDATE THE CLASSIFICATION OF HEART FAILURE AS HEART FAILURE WITH OR WITHOUT EVIDENCE OF SYSTOLIC DYSFUNCTION?
21. FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL
22. EMPAGLIFLOZIN IN PATIENTS HOSPITALIZED FOR DE NOVO VERSUS DECOMPENSATED CHRONIC HEART FAILURE: INSIGHTS FROM THE EMPULSE TRIAL
23. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
24. LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events
25. Quality of Life Always Matters
26. Use of Outpatient Intravenous Calcitropes for Heart Failure in the United States
27. Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review
28. Empagliflozin in Patients Hospitalised for De Novo Versus Decompensated Chronic Heart Failure: Insights From the EMPULSE Trial
29. Empower the Future… Even Oprah Had a Mentor!
30. IS EARLY INITIATION OF MECHANICAL CIRCULATORY SUPPORT ASSOCIATED WITH IMPROVED IN-HOSPITAL MORTALITY DUE TO ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK
31. Pragmatic Design of Randomized Clinical Trials for Heart Failure
32. ALTERED NEUROLOGICAL STATUS, INTRACRANIAL HEMORRHAGE AND SEVERE INTRACRANIAL HYPERTENSION COMPLICATING POST-TRANSPLANT CARE: A DIAGNOSTIC DILEMMA
33. Kidney, You Are My Friend
34. Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy
35. Treatment of HF in an Era of Multiple Therapies
36. Navigating Early Careers in Heart Failure in the Era of Novel Coronavirus Disease-2019
37. Promoting Health Equity in Heart Failure Amid a Pandemic
38. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
39. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation
40. Conduct of Clinical Trials in the Era of COVID-19
41. A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
42. The Influence of Age and Gender on Outcomes and Healthcare Cost Among Older Adults Hospitalized with Acute Systolic Heart Failure
43. Disposition Status and Healthcare Cost Among Older Adults Hospitalized with Acute Systolic Heart Failure
44. Restricted Mean Survival Time for Analysis and Interpretation of Clinical Trials for Heart Failure Devices
45. Torsemide Is Associated with Higher Levels of Urinary Biomarkers of Tubular Injury Compared to Furosemide
46. Reply
47. The Association Between Secondhand Smoke Exposure and Survival for Patients With Heart Failure
48. Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19
49. Assessing the lifetime benefit of heart failure therapies
50. PECAM-1 is Associated WithOutcomes and Response to Treatment in Pulmonary Arterial Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.